Compugen Reports Q2 Progress with MAIA-Ovarian Trial and Strong Cash Position
Compugen Ltd. (NASDAQ:CGEN) reported progress in its second quarter of fiscal year 2026, including continued enrollment in the MAIA-ovarian trial for COM701, a potential first-in-class anti-PVRIG antibody being tested as maintenance monotherapy for relapsed platinum-sensitive ovarian cancer patients. The company expects an interim analysis with median progression-free survival data by Q1 2027 and estimates that the placebo arm's median PFS is around four months based on external studies. Compugen also highlighted its strong financial position, reporting $125.3 million in cash and investments as of June 30, 2026, with a projected runway extending into 2029 without additional funding. Second-quarter revenue increased to $2.6 million from negligible levels previously, while the net loss narrowed slightly year-over-year. The company remains eligible for up to $195 million in milestones and tiered royalties under its partnership with AstraZeneca (NASDAQ:AZN), which is expanding development of rilvegostomig into a 12th Phase III trial. Management described the quarter as one of 'steady advancement' across clinical programs, collaborations, and discovery activities.
Tickers: $AZN